Ocugen is a Pennsylvania-based biopharmaceutical company that discovers, develops and commercializes therapies for the treatment of ocular disorders.
Business Model:
Revenue: $42.6k
Employees: 51-200
Address: 263 Great Valley Pkwy,
City: Malvern
State: PA
Zip: 19355
Country: US
Ocugen is a Pennsylvania-based biopharmaceutical company that discovers, develops and commercializes therapies for the treatment of ocular disorders.
Contact Phone:
+14843284701
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
4/8/2019
Ticker Symbol:
OCGN
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 9/2019 | Private Placement | $25M | 4/2021 | Post-IPO Equity | $0 |
ROTH Capital Partners ROTH Capital Partners |
4/2020 | Debt | $350k |
U.S. Small Business Administration. |
2/2021 | Post-IPO Equity | $23M | 2/2022 | Post-IPO Equity | $53.5M | 4/2020 | Debt | $421.4k |
Silicon Valley Bank Small Business Administration |
12/2016 | Series A | 3 | $6M |
Bernhard Hampl Ahsan M. Nasratullah EB5 Life Sciences Bernhard Hampl Ahsan M. Nasratullah EB5 Life Sciences |
6/2017 | Series B | 4 | $7.5M |
Abdi Ibrahim Pharmaceuticals Lancaster Group Frank Leo John Zhang Abdi Ibrahim Pharmaceuticals Lancaster Group Abdi Ibrahim Pharmaceuticals Lancaster Group Frank Leo John Zhang Abdi Ibrahim Pharmaceuticals Lancaster Group |
4/2021 | Post-IPO Equity | 1 | $100M |
ROTH Capital Partners |
---|
Announced Date | Name | Price |
---|---|---|
9/2019 | Histogenics |
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|